Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: Strong contribution of TNFα receptors to PAI-1 levels

Thrombosis and Haemostasis

Volumn 88, Issue 3, 2002, Pages 481-487

  Bastelica, Delphine ^a   Mavri, Alenka ^a   Verdier, Monique ^a   Berthet, Bruno ^a   Juhan Vague, Irène ^a   Alessi, Marie Christine ^a  

^a Laboratoire d'Hématologie   (France)

Author keywords

Human adipose tissue; Inflammatory cytokines; PAI 1; Plasminogen activators

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; FIBRINOGEN; INSULIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UROKINASE; BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADIPOSE TISSUE; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFLAMMATION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MODEL; OBESITY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; ADULT; BLOOD; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036712296     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613241     Document Type: Article

References (49)

1. The plasminogen activator/plasmin system
2. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue
3. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
4. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice
5. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
6. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
7. Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-alpha?
8. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals
9. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
10. Plasminogen activator inhibitor 1, transforming growth factor beta 1 and BMI are closely associated in human adipose tissue during morbid obesity
11. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice
12. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity
13. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects
14. Elevated C-reactive protein levels in overweight and obese adults
15. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
16. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity
17. C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors
18. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity
19. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
20. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
21. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
22. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
23. Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: Results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by Urokinase Enhancement
24. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells
25. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor
26. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators
27. Measurement of urokinase type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies
28. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
29. Urokinase plasminogen activator system in humans with stable coronary artery disease
30. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
31. Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients
32. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects
33. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo
34. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity
35. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study
36. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss
37. Related plasma concentrations of soluble TNF-alpha receptors in obese subjects
38. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance
39. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance
40. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: Relationship to elevated TPA antigen in patients with high PAI-1 activity levels
41. Haemostasis factors in angina pectoris; Relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group
42. Involvement of the hemostatic system in the insulin resistance syndrome
43. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
44. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects
45. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
46. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects
47. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
48. Obesity and diabetes in TNF-alpha deficient mice